Navigation Links
Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
Date:9/14/2009

MONMOUTH JUNCTION, N.J., Sept. 14 /PRNewswire/ -- Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density. In addition, ARIKACE was well-tolerated with overall adverse events comparable to placebo. Results were presented today at the European Respiratory Society Meeting in Vienna, Austria by Anne E. O'Donnell, MD, Professor of Medicine and Chief of the Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown University Hospital, and co-lead investigator of the study.

The double-blind, placebo-controlled study was designed to evaluate ARIKACE in non-CF patients who have bronchiectasis with Pseudomonas lung infections. Sixty-four adult patients were randomized to receive ARIKACE - either 280 mg or 560 mg daily dosages - or placebo. Patients received 28 days of therapy followed by a 28-day off-treatment observation period. ARIKACE and placebo were administered once daily using an eFlow (R) Nebulizer System (PARI Pharma GmbH), a novel, highly efficient, portable aerosol delivery system. Sixteen clinical sites throughout Europe and India participated in the study.

"The positive efficacy and tolerability profile demonstrated by ARIKACE in this study is encouraging for non-CF bronchiectasis patients that have pseudomonas lung infections and for physicians who treat them," said Dr. O'Donnell. "These successful results with ARIKACE are especially important since there is nothing currently approved to treat bronchiectasis patients with these types of infections."'/>"/>

SOURCE Transave, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
2. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
3. Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
4. Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
5. ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
6. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
7. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
8. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
9. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
10. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
11. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 ... the addition of the "Endoscopy Global Market ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... approximately $43 billion by 2019 growing at around ... drivers for the market growth are aging population, ...
(Date:4/27/2015)... April 27, 2015  Eiger BioPharmaceuticals, Incorporated today announced ... of lonafarnib in patients with chronic hepatitis delta viral ... program, enrolled at Ankara University Medical School, ... endemic. LOWR HDV - 1 (LOnafarnib ... study which randomized subjects to receive different doses of ...
(Date:4/27/2015)... di Reggio Emilia, the Regional Health Service office for ... Zebra Technologies Corporation (NASDAQ: ZBRA ) wireless ... (WNS) provided by Zebra has allowed staff to ... via mobile computers, contributing to improved patient care with ... and guest Wi-Fi access and enables hospital staff to ...
Breaking Medicine Technology:Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5
... Corporation (NYSE: SGP ) today reported that interim ... (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent ... virus (HCV) genotype 1. In the lead-in arms ... lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) ...
... Sciences, Inc. (Nasdaq: CALP ), a leading provider of ... from the United States Food and Drug Administration (FDA) on ... screening and characterization assays for biological drugs. , "We were ... platform to a large group of reviewers. We believe the ...
Cached Medicine Technology:Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration 2
(Date:4/27/2015)... Clyde, NC (PRWEB) April 27, 2015 ... residents will conclude a social media campaign to raise ... and developer, Michael Mamas; and Sri Somesvara Temple. Ironically, ... Ridge Mountains of North Carolina, they thought they were ... commit to at least six months of meditation, service ...
(Date:4/27/2015)... 2015 Telematics Berlin is Europe’s biggest ... associations, CE players and the government to discuss the ... the car. This year’s panel on connected car security ... European Commission, is an opportunity to hear and contribute ... European Automotive Security Standard for years to come. ...
(Date:4/27/2015)... Chicago and its seven surrounding counties ... make area communities healthier, more sustainable and more beautiful. ... every five parkway trees likely to soon be destroyed ... this tree “tipping point,” Chicago-area residents are concerned, as ... Morton Arboretum . The Lisle, Illinois-based tree-focused institution’s Talking ...
(Date:4/27/2015)... The global coagulation analyzers market is estimated to ... however, it is expected to witness high growth ... Brazil in the next five years. Growth in ... such as increasing adoption of automated hemostasis instruments ... developments in high-sensitivity point-of-care coagulation analyzers and introduction ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 The Mount ... a seamless referral process for the Health System’s care ... heart failure or diabetes, for instance, may have more ... physicians coordinate with many other care providers. With medical ... of thousands of patients each year, the need for ...
Breaking Medicine News(10 mins):Health News:Mount Soma Monks Do Social Media 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 2Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 4Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 3Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... A new study shows obesity may increase the risk ... by researchers at the National Institutes of Health, reveals ... adenocarcinoma than with squamous cell carcinoma. ,The study ... carcinoma, and 307 women without cancer as the control ...
... year, about 12,000 cases of cancer of the larynx are ... will have to have a laryngectomy// - taking away their ... new alternative that's giving patients their voices back. ,For ... no voice. "Some things you do not forget, and that ...
... to prevent bone loss may also help prevent prostate cancer ... United Kingdom indicates oral sodium clodronate may slow the spread ... death. //This is a drug commonly used to prevent bone ... in about 85 percent of men. The researchers recruited 311 ...
... done previously have shown that the hormone could suppress ... would not work in obese people because studies of another ... do a second trial to see if obese people were ... they are. They're just as sensitive as thin people." ...
... to eat healthier. A new study finds whole grains, fruits ... your overall risk of dying. However, the study also reports ... stroke. ,The U.S. Dietary Guidelines for Americans include choosing ... variety of grains daily, especially whole grains. While at least ...
... who suffer from asthma do not meet the right ... activity// of adults with asthma. Knowing if asthma patients ... health professionals in designing fitness programs for asthma patients. ... Prevention conducted a study to look at the physical ...
Cached Medicine News:Health News:A voice saving surgery 2Health News:Extra hormone found to cut appetite by a third 2
... compact system provides an ideal solution ... the laboratory, satellite lab and the ... staining method with wedge-smear technology, the ... standardization in a safe enclosed environment. ...
It is a cardio-pulmonary exercise testing device....
... Q-Stress Treadmill has digitally-controlled drive ... moving parts that can wear out. ... speed change mechanism, and fewer drive ... level of dependability. It can carry ...
... feature our internationally-acclaimed algorithm that is ... has a proven record for reliability ... and it's just one of several ... market leader in the stress testing ...
Medicine Products: